Notch Therapeutics
Michael Hunter Cadell possesses extensive experience in research roles within the biotechnology and academic sectors. Currently serving as a Senior Research Associate at Notch Therapeutics since June 2022, Michael has previously held similar positions at Universal Cells and served as a Research Specialist B at the University of Pennsylvania School of Medicine. Michael's background includes research technician roles at OHSU and the University of California, Santa Cruz, as well as a foundational experience as a Lab Research Assistant at The University of Texas at Austin. Michael earned a Bachelor's degree in Biology with an emphasis on Chemistry from The University of Texas at Austin.
This person is not in any offices
Notch Therapeutics
Notch is an immune cell therapy company developing a next-generation pipeline of off-the-shelf, universally compatible, genetically tailored T cell therapeutics derived from renewable stem cell sources for the treatment of high-impact diseases, with an initial focus on cancer.